LONDON and NEW YORK, April 24, 2024 MeiraGTx Holdings plc , a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief.
MeiraGTx to receive $50 million milestone after initiation of the extension study for the Phase 3 LUMEOS clinical trial for botaretigene sparoparvovec for the treatment of X-linked retinitis.
- MeiraGTx enters into an Asset Purchase Agreement related to botaretigene sparoparvovec for the treatment of X-linked retinitis pigmentosa for a total of up to $415 million - MeiraGTx to receive.
- MeiraGTx enters into an Asset Purchase Agreement related to botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of X-linked retinitis pigmentosa (XLRP) for a total of up to $415
MeiraGTx Announces Third Quarter 2023 Financial and Operational Results streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.